

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization

International Bureau

(43) International Publication Date
02 December 2021 (02.12.2021)



(10) International Publication Number
WO 2021/239558 A1

(51) International Patent Classification:

C07D 487/04 (2006.01) A61K 31/519 (2006.01)

A61P 29/02 (2006.01)

EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

(21) International Application Number:

PCT/EP2021/063411

(22) International Filing Date:

20 May 2021 (20.05.2021)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

20382447.9 27 May 2020 (27.05.2020) EP

(71) Applicant: **ESTEVE PHARMACEUTICALS, S.A.**
[ES/ES]; Passeig de la Zona Franca, 109, 4^a Planta, 08038
Barcelona (ES).

(72) Inventors: **FERNANDEZ-DONIS, Ariadna**; C/ Calabria
146, 08015 Barcelona (ES). **DÍAZ-FERNÁNDEZ, José-
Luís**; c/ Cadi, 21, 08242 Manresa Barcelona (ES). **AL-
MANSA-ROSALES, Carmen**; C/Teodora Lamadrid, n°
41, Ent 4^a, 08022 Barcelona (ES). **GARCIA-LOPEZ,
Monica**; Gran Via de les Corts Catalanes, 911, 2^a-1^a, 08018
Barcelona (ES). **FERNANDEZ-COLLADO, Joan-Car-
les**; Gran Via de les Corts Catalanes 232, 5^a, 1^a, 08004
Barcelona (ES). **GONZALEZ-GARCIA, Jordi**; C/ Colón
24, 08640 Olesa de Montserrat Barcelona (ES). **GARRI-
DO-MARTINEZ, Maria**; C/ Jaume Puigvert 5, 1^a, 1^a,
08024 Barcelona (ES).

(74) Agent: **MARTIN, Roberto**; ESTEVE PHARMACEUTI-
CALS S.A., Pg. de la Zona Franca, 109, 4^a Planta, 08038
BARCELONA (ES).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO,
DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN,
HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN,
KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD,
ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO,
NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW,
SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN,
TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, GH,
GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ,
UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ,
TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK,

(54) Title: PYRAZOLO[1,5-A]PYRIMIDINE DERIVATIVES HAVING MULTIMODAL ACTIVITY AGAINST PAIN

(57) Abstract: The present invention relates to pyrazolopyrimidine derivatives having dual pharmacological activity towards both the $\alpha_2\delta$ subunit of the voltage-gated calcium channel and the sigma-1 (σ_1) receptor, to processes of preparation of such compounds, to pharmaceutical compositions comprising them, and to their use in therapy, in particular for the treatment of pain.

WO 2021/239558 A1